|Name||PRICE||MARKET CAPITALIZATION||PRICE TO EARNINGS RATIO||DIVIDEND YIELD||SYMBOL||EXCHANGE||PRICE PERCENT DIFFERENCE||YEAR TO DATE PRICE PERCENT DIFFERENCE||5 YEAR CHART||1 YEAR CHART|
Medgenics (known as Aevi Genomic Medicine since December 2016) is a clinical-stage biopharmaceutical company involved mainly in genomic medicine. Genomic medicine involves the usage of individual's genomic information to decide upon clinical care. This medical discipline is used in the fields of oncology, pharmacology, rare and undiagnosed diseases, and infectious diseases. Medgenics' partner is the Center for Applied Genomics at the Children's Hospital of Philadelphia, with which it works to develop drugs by implementing genomics medicine. The firm's portfolio includes TARGT, for treatment of end-stage renal disease; ÃŽÂ²-thalassemia intermedia (Thalassemia patients require blood transfusion); and other developments.
GNMX $0.21 -0.01 (-4.55%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 10 Million
EPS -0.12 P/E Ratio 0.00
Previous Earnings Thu, Aug 2, 2018
Latest Earnings Thu, Nov 1, 2018
Dividend Pay Date --
Dividend History --
Investing Quotes #Legendary
Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.
Some links on this website are advertisements and/or affiliate links and Symbol Surfing receives compensation.